Asahi Kasei Pharma begins phase III study of promising CIPN prevention therapy, Recomodulin to enhance treatment options worldwide: Chelmsford, Massachusetts Thursday, July 3, 202 ...

CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO, July 02, 2025--Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan for CIPN.

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Experts have warned three popular supplements people are needlessly taking could do more harm than good, and even be fatal.

The challenges of getting face-to-face appointments with GPs since the pandemic have contributed to costly mistakes being ...

Diabetic neuropathy, a common complication of uncontrolled diabetes can cause burning, tingling, numbness, and sharp pain, especially in the feet and hands. While medications are available ... Lee ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was ...